Elite 50% OFF Act now – get top investing tools Register Now!

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Latest News

Nov-23	2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon VRTX Motley Fool
Nov-21	Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why VRTX StockStory
Nov-20	Analyst Report: CRISPR Therapeutics AG VRTX Morningstar Research
Nov-20	2 Inflation-Proof Growth Stocks That Could Outperform the Market VRTX Motley Fool
Nov-19	Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3 VRTX Business Wire
Nov-18	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know VRTX Zacks
Nov-18	Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings VRTX Barchart
Nov-18	Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target VRTX Insider Monkey
Nov-17	1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November VRTX Motley Fool
Nov-16	My 3 Favorite Stocks to Buy Right Now VRTX Motley Fool
Nov-13	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls VRTX The Fly
Nov-11	Analyst Report: CRISPR Therapeutics AG VRTX Morningstar Research
Nov-11	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates VRTX Zacks
Nov-10	5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call VRTX StockStory
Nov-08	Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week VRTX Business Wire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.